Yeah? Try going to Europe"
The situation with foreign country sales can be quite different. In order to remain viable, US drug companies must be prudent with US sale price in order to recover the $2.5 billion cost of approvals to sell in the US. Keep in mind, the production cost of most drugs is near zero in comparison. When they can also sell the drugs in other countries with controlled prices, it is also prudent to sell them there at the controlled price. It's counterproductive to allow reimporting these at the controlled price, when the R&D costs have not been recovered.
I say again, the problem is the cost of FDA approvals, not drug company greed. If you are going to convince me of drug company greed, you're going to have to show me a drug company with excessive profits.
"Excessive profits"... now there's an Orwellian term if I've ever heard one. That's no measure of a company's ethics; a better measure is the company's ethics. Do they spend as much money on lobbying as they do R&D? Do they engage in activity in restraint of trade? Do they, in short, try to 'fix the game' in their favor?